Compare Gilead Sciences, Inc. (GILD) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Public Storage — how do they compare? Gilead Sciences, Inc. trades at $133.09 (market cap $163.51B), while Public Storage trades at $320.72 (market cap $55.25B). The key difference: Gilead Sciences, Inc. is far larger — about 3× Public Storage's market cap, and Public Storage pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| GILD | PSA | |
|---|---|---|
Market Cap | $163.51B | $55.25B |
Sector | Health | Real Estate |
52-Week High | $155.80 | $329.64 |
52-Week Low | $108.22 | $258.44 |
Enterprise Value | $178.05B | $69.50B |
Dividend Yield | 2.49% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Public Storage (PSA) trades at $318.93, down 0.91% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company maintains strong profitability with a 39.16% net income margin and has beaten earnings estimates for three consecutive quarters. Recent developments include the pending acquisition of National Storage Affiliates and a $3.00 dividend payment scheduled for June 30, 2026.
PSA offers growth potential through strategic acquisitions and operational efficiency, supported by analyst consensus price target of $332.25. Risks include integration challenges from acquisitions and sensitivity to interest rate changes. The stock presents a balanced opportunity for investors seeking stable dividends and expansion in the self-storage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
